Values Added Financial LLC Increases Position in Abbott Laboratories $ABT

Values Added Financial LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 42.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,571 shares of the healthcare product maker’s stock after purchasing an additional 1,066 shares during the period. Values Added Financial LLC’s holdings in Abbott Laboratories were worth $486,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Hughes Financial Services LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories during the 1st quarter worth approximately $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories during the 1st quarter worth approximately $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories during the 1st quarter worth approximately $32,000. Finally, Vision Financial Markets LLC purchased a new stake in Abbott Laboratories during the 1st quarter worth approximately $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $134.45 on Thursday. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23. The firm has a market capitalization of $234.00 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The business has a 50 day simple moving average of $132.30 and a 200-day simple moving average of $131.48. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ABT. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Evercore ISI boosted their price objective on Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a research note on Tuesday. Royal Bank Of Canada boosted their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Jefferies Financial Group upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, Mizuho upped their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $146.24.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.